Blog
RSS FeedPosted by Michael Wonder on 13 Oct 2016
Substantial rebates negotiated in Medicare Part D
12 October 2016 - A new QuintilesIMS Institute research brief takes a first-of-its-kind look at Part D costs after accounting ...
Posted by Michael Wonder on 13 Oct 2016
Valeant hiked lead poisoning drug price by 2,700 per cent: report
11 October 2016 - Valeant Pharmaceuticals hiked the price of a widely used treatment for life-threatening cases of lead poisoning ...
Posted by Michael Wonder on 12 Oct 2016
Undermining value-based purchasing — lessons from the pharmaceutical industry
12 October 2016 - In 2015, the U.S. Department of Health and Human Services announced a goal of linking at ...
Posted by Michael Wonder on 12 Oct 2016
FDA grants QIDP and fast track designations to VT-1161 for treatment of recurrent vulvovaginal candidiasis
12 October 2016 - Viamet Pharmaceuticals today announced that the U.S. FDA has granted Qualified Infectious Disease Product and fast ...
Posted by Michael Wonder on 12 Oct 2016
Improved quality of Medicare health and drug plans means great news for Medicare beneficiaries
12 October 2016 - The Centers for Medicare & Medicaid Services is preparing for the annual Medicare Open Enrollment, which ...
Posted by Michael Wonder on 12 Oct 2016
What experimental drug? Most companies don’t post compassionate use policies
11 October 2016 - As patients clamour for greater access to experimental medicines, a survey released Tuesday finds that ...
Posted by Michael Wonder on 11 Oct 2016
Battling rising drug prices is like 'whac-a-mole,' says hospital executive
11 October 2016 - Inpatient hospital drug costs rose about 38% to $990 per patient admission between 2013 and 2015, ...
Posted by Michael Wonder on 11 Oct 2016
FDA grants priority review to Roche's Lucentis for mCNV
11 October 2016 - The U.S. FDA has granted priority review for Roche drug Lucentis (ranibizumab) for treating myopic choroidal ...
Posted by Michael Wonder on 11 Oct 2016
ICER releases corrected evidence report on treatments for non-small-cell lung cancer
7 October 2016 - PD-1 value-based price benchmarks are updated while the main conclusions of the analysis remain unchanged. ...
Posted by Michael Wonder on 10 Oct 2016
Elbit Imaging announces that Gamida Cell has received FDA breakthrough therapy designation for Nicord
10 October 2016 - Elbit Imaging announced today that it was informed by Gamida Cell, an indirect associate of the ...
Posted by Michael Wonder on 10 Oct 2016
Anthem says will not cover Sarepta's approved Duchenne drug
7 October 2016 - Health insurer Anthem said it will not cover Sarepta Therapeutics Inc's medicine to treat patients with ...
Posted by Michael Wonder on 10 Oct 2016
U.S. FDA approves Carnexiv (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations
7 October 2016 - U.S. FDA approves Carnexiv (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations. ...
Posted by Michael Wonder on 09 Oct 2016
Teva and Celltrion announce exclusive biosimilar commercial partnership
6 October 2016 - Teva Pharmaceutical Industries Ltd and Celltrion Healthcare have announced that the companies have entered into an exclusive ...
Posted by Michael Wonder on 09 Oct 2016
Coherus Biosciences announces FDA acceptance of 351(K) biologics license application to U.S. FDA for CHS-1701 (pegfilgrastim biosimilar candidate)
6 October 2016 - Coherus BioSciences today announced that the U.S. FDA has accepted the filing of 351(k) biologics license ...
Posted by Michael Wonder on 09 Oct 2016
Muscular dystrophy drug looks set for commercial success despite clinical doubts
3 October 2016 - A newly approved drug to treat Duchenne muscular dystrophy seems likely to be used by most ...